Clearmind Financial Statements From 2010 to 2026

CMND Stock  USD 2.17  0.02  0.91%   
Clearmind Medicine's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Clearmind Medicine's valuation are provided below:
Market Capitalization
3.3 M
Earnings Share
(30.35)
There are over one hundred nineteen available fundamental signals for Clearmind Medicine Common, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Clearmind Medicine's prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of February 1, 2026, Market Cap is expected to decline to about 3.6 M. In addition to that, Enterprise Value is expected to decline to about 2.5 M
Check Clearmind Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clearmind Medicine's main balance sheet or income statement drivers, such as Interest Expense of 29.9 K, Selling General Administrative of 2.3 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.7. Clearmind financial statements analysis is a perfect complement when working with Clearmind Medicine Valuation or Volatility modules.
  
Build AI portfolio with Clearmind Stock
Check out the analysis of Clearmind Medicine Correlation against competitors.

Clearmind Medicine Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.3 M9.8 M3.1 M
Slightly volatile
Total Current Liabilities8.3 M7.9 M2.2 M
Slightly volatile
Accounts Payable1.2 M1.1 M400.7 K
Slightly volatile
Cash6.6 M6.3 M2.3 M
Slightly volatile
Other Current Assets61.2 K64.4 K84.6 K
Pretty Stable
Total Liabilities8.3 M7.9 M2.2 M
Slightly volatile
Short and Long Term Debt2.1 MM1.2 M
Slightly volatile
Total Current Assets10.1 M9.6 M2.9 M
Slightly volatile
Short Term DebtM2.9 M525.2 K
Slightly volatile
Common Stock44.7 M42.6 M11.4 M
Slightly volatile
Other Current Liabilities4.1 M3.9 M1.3 M
Slightly volatile
Property Plant And Equipment Net20.9 K22 K51.5 K
Very volatile
Non Current Assets Total230.8 K218.1 K144 K
Slightly volatile
Cash And Short Term Investments9.5 MM2.7 M
Slightly volatile
Net Receivables545.5 K519.5 K134.6 K
Slightly volatile
Common Stock Shares Outstanding153.5 K146.2 K35.5 K
Slightly volatile
Liabilities And Stockholders Equity10.3 M9.8 M3.1 M
Slightly volatile
Other Stockholder Equity2.4 M4.3 M1.5 M
Slightly volatile
Property Plant Equipment85.2 K59.7 K114.3 K
Slightly volatile
Capital Stock31.9 M30.4 M8.9 M
Slightly volatile
Property Plant And Equipment Gross14.9 K15.7 K124.5 K
Slightly volatile
Other Assets16.3 K17.2 K35.4 K
Pretty Stable
Intangible Assets132.3 K122.8 K180.1 K
Slightly volatile
Short and Long Term Debt TotalM2.9 M537.9 K
Slightly volatile
Deferred Long Term Liabilities216.4 K243.4 K265.7 K
Slightly volatile

Clearmind Medicine Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative2.3 M4.1 M1.7 M
Slightly volatile
Total Operating Expenses9.5 M9.1 M3.3 M
Slightly volatile
Other Operating Expenses4.6 M9.1 MM
Slightly volatile
Depreciation And Amortization76.8 K62.3 K119.7 K
Slightly volatile
Selling And Marketing Expenses697.4 K1.3 M378.5 K
Slightly volatile

Clearmind Medicine Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock60.4 K57.5 K39.6 K
Slightly volatile
Total Cash From Financing Activities3.1 M4.2 M2.4 M
Slightly volatile
End Period Cash Flow6.6 M6.3 M2.3 M
Slightly volatile
Begin Period Cash Flow11.1 M10.6 M2.6 M
Slightly volatile
Depreciation67.3 K62.3 K121.2 K
Slightly volatile
Change To NetincomeM2.9 M1.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables4.8 K6.1 K5.1 K
Slightly volatile
Capex To Depreciation0.09990.1138.0576
Slightly volatile
Payables Turnover0.07780.120.0477
Slightly volatile
Cash Per Share52.6655.44650
Very volatile
Days Payables OutstandingK3.1 K27.3 K
Slightly volatile
Income Quality0.761.11.097
Slightly volatile
Intangibles To Total Assets0.01750.01840.0392
Pretty Stable
Net Debt To EBITDA0.630.666.8374
Slightly volatile
Current Ratio1.331.44.021
Very volatile
Capex Per Share7.668.0676.8354
Pretty Stable
Average Receivables199 K189.5 K73 K
Slightly volatile
Interest Debt Per Share32.5322.8152.2622
Slightly volatile
Debt To Assets0.280.260.0826
Slightly volatile
Days Of Payables OutstandingK3.1 K27.3 K
Slightly volatile
Ebt Per Ebit1.060.770.88
Slightly volatile
Quick Ratio1.331.44.0256
Very volatile
Net Income Per E B T0.820.920.9935
Slightly volatile
Cash Ratio0.880.923.7336
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.661.151.9686
Slightly volatile
Debt Ratio0.280.260.0826
Slightly volatile

Clearmind Medicine Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.6 M5.1 M3.9 M
Slightly volatile

Clearmind Fundamental Market Drivers

About Clearmind Medicine Financial Statements

Clearmind Medicine stakeholders use historical fundamental indicators, such as Clearmind Medicine's revenue or net income, to determine how well the company is positioned to perform in the future. Although Clearmind Medicine investors may analyze each financial statement separately, they are all interrelated. For example, changes in Clearmind Medicine's assets and liabilities are reflected in the revenues and expenses on Clearmind Medicine's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Clearmind Medicine Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue79.6 K47 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:
Check out the analysis of Clearmind Medicine Correlation against competitors.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Biotechnology sector continue expanding? Could Clearmind diversify its offerings? Factors like these will boost the valuation of Clearmind Medicine. Projected growth potential of Clearmind fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Clearmind Medicine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(30.35)
Return On Assets
(0.53)
Return On Equity
(1.79)
Understanding Clearmind Medicine Common requires distinguishing between market price and book value, where the latter reflects Clearmind's accounting equity. The concept of intrinsic value—what Clearmind Medicine's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Clearmind Medicine's price substantially above or below its fundamental value.
It's important to distinguish between Clearmind Medicine's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Clearmind Medicine should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Clearmind Medicine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.